Allergische Reaktionen der Lunge

详细信息    查看全文

• 作者：A.R. Koczulla (1) koczulla@med.uni-marburg.de
  B. Beutel (1)
  T. Greulich (1)
  A. Jerrentrup (1)
  C. Vogelmeier (1)
• 关键词：Hypersensitivity – Bronchial asthma – Aspergillosis ; allergic bronchopulmonary – Churg ; Strauss syndrome – Alveolitis ; extrinsic allergic
• 刊名：Der Internist
• 出版年：2012
• 出版时间：August 2012
• 年：2012
• 卷：53
• 期：8
• 页码：924-933
• 全文大小：785.1 KB
• 参考文献：1. Virchow JC (2010) Asthma—historical development, current status and perspectives. Pneumologie 64:541–549
  2. Ishizaka K, Ishizaka T (1976) Immunoglobulin E. Current status and clinical laboratory applications. Arch Pathol Lab Med 100:289–292
  3. Ishizaka T, Ishizaka K, Tomioka H (1972) Release of histamine and slow reacting substance of anaphylaxis (SRS-A) by IgE-anti-IgE reactions on monkey mast cells. J Immunol 108:513–520
  4. Evans DJ, Barnes PJ, Cluzel M, O’Connor BJ (1997) Effects of a potent platelet-activating factor antagonist, SR27417A, on allergen-induced asthmatic responses. Am J Respir Crit Care Med 156:11–16
  5. Mosmann TR, Cherwinski H, Bond MW et al (1986) Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 136:2348–2357
  6. Galli SJ, Tsai M, Piliponsky AM (2008) The development of allergic inflammation. Nature 454:445–454
  7. Dvorak A (2005) Ultrastructural studies of human basophils and mast cells. J Histochem Cytochem 53:1043–1070
  8. Galli SJ, Kalesnikoff J, Grimbaldeston MA et al (2005) Mast cells as ?tunable“ effector and immunoregulatory cells: recent advances. Annu Rev Immunol 23:749–786
  9. Bradding P, Walls AF, Holgate ST (2006) The role of the mast cell in the pathophysiology of asthma. J Allergy Clin Immunol 117:1277–1284
  10. Marshall J (2004) Mast-cell responses to pathogens. Nat Rev Immunol 4:787–799
  11. Bradding P, Holgate ST (1996) The mast cell as a source of cytokines in asthma. Ann N Y Acad Sci 796:272–281
  12. Howarth PH, Bradding P, Quint D et al (1994) Cytokines and airway inflammation. Ann N Y Acad Sci 72:69–82
  13. Cevikbas F, Steinhoff A, Homey B, Steinhoff M (2007) Neuroimmune interactions in allergic skin diseases. Curr Opin Allergy Clin Immunol 7:365–373
  14. Lalloo UG, Barnes PJ, Chung KF (1996) Pathophysiology and clinical presentations of cough. J Allergy Clin Immunol 98(5 Pt 2):91–96
  15. Sarin S, Undem B, Sanico A, Togias A (2006) The role of the nervous system in rhinitis. J Allergy Clin Immunol 118:999–1016
  16. Sampson HA, Mu?oz-Furlong A, Bock SA et al (2005) Symposium on the definition and management of anaphylaxis: summary report. J Allergy Clin Immunol 115:584–591
  17. Kay A (2001) Allergy and allergic diseases. First of two parts. N Engl J Med 344:30–37
  18. Kay A (2001) Allergy and allergic diseases. Second of two parts. N Engl J Med 344:109–113
  19. Galli SJ, Grimbaldeston M, Tsai M (2008) Immunomodulatory mast cells: negative, as well as positive, regulators of immunity. Nat Rev Immunol 8:478–486
  20. Holgate ST (2007) Epithelium dysfunction in asthma. J Allergy Clin Immunol 120:1233–1244 (Quiz: 1245–1246)
  21. Holgate ST (2007) The epithelium takes centre stage in asthma and atopic dermatitis. Trends Immunol 28:248–251
  22. Knutsen AP, Bellone C, Kauffman H (2002) Immunopathogenesis of allergic bronchopulmonary aspergillosis in cystic fibrosis. J Cyst Fibros 1:76–89
  23. Reed CE (2007) Inflammatory effect of environmental proteases on airway mucosa. Curr Allergy Asthma Rep 7:368–374
  24. Knight DA, Lim S, Scaffidi AK et al (2001) Protease-activated receptors in human airways: upregulation of PAR-2 in respiratory epithelium from patients with asthma. J Allergy Clin Immunol 108:797–803
  25. Pagnoux C, Guilpain P, Guillevin L (2007) Churg-Strauss syndrome. Curr Opin Rheumatol 19:25–32
  26. Dallos T, Heiland GR, Strehl J et al (2010) CCL17/thymus and activation-related chemokine in Churg-Strauss syndrome. Arthritis Rheum 62:3496–3503
  27. Kiene M, Csernok E, Müller A et al (2001) Elevated interleukin-4 and interleukin-13 production by T cell lines from patients with Churg-Strauss syndrome. Arthritis Rheum 44:469–473
  28. Szczeklik W, Jakie?a B, Adamek D, Musia? J (2011) Cutting edge issues in the Churg-Strauss syndrome. Clin Rev Allergy Immunol (im Druck)
  29. Jakiela B, Sanak M, Szczeklik W et al (2011) Both Th2 and Th17 responses are involved in the pathogenesis of Churg-Strauss syndrome. Clin Exp Rheumatol 29(1 Suppl 64):23–34
  30. Tsurikisawa N, Saito H, Tsuburai T et al (2008) Differences in regulatory T cells between Churg-Strauss syndrome and chronic eosinophilic pneumonia with asthma. J Allergy Clin Immunol 122:610–616
  31. Bourke SJ, Dalphin JC, Boyd G et al (2001) Hypersensitivity pneumonitis: current concepts. Eur Respir J Suppl 32:81s–92s
  32. Ando M, Suga M, Kohrogi H (1999) A new look at hypersensitivity pneumonitis. Curr Opin Pulm Med 5:299–304
  33. McFadden ER Jr, Lenner KA, Strohl KP (1986) Postexertional airway rewarming and thermally induced asthma. New insights into pathophysiology and possible pathogenesis. J Clin Invest 78:18–25
  34. http://www.goldcopd.com
  35. Global Initiative for Asthma. http://www.ginaasthma.org
  36. Abramson MJ, Puy RM, Weiner JM (2010) Injection allergen immunotherapy for asthma. Cochrane Database Syst Rev 8:CD001186
  37. Jacobsen L, Niggemann B, Dreborg S et al (2007) Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy 62:943–948
  38. Thomson NC, Chaudhuri R, Spears M (2011) Emerging therapies for severe asthma. BMC Med 9:102
  39. Rodrigo GJ, Neffen H, Castro-Rodriguez JA (2011) Efficacy and safety of subcutaneous omalizumab vs. placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review. Chest 139:28–35
  40. Leckie MJ (2003) Anti-interleukin-5 monoclonal antibodies: preclinical and clinical evidence in asthma models. Am J Respir Med 2:245–259
  41. Haldar P, Brightling CE, Hargadon B et al (2009) Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 360:973–984
  42. Pavord ID, Haldar P, Bradding P, Wardlaw AJ (2010) Mepolizumab in refractory eosinophilic asthma. Thorax 65:370
  43. Zarogiannis S, Gourgoulianis KI, Kostikas K (2009) Anti-interleukin-5 therapy and severe asthma. N Engl J Med 360:2576 (Autorenantwort: 2577)
  44. Siegle JS, Hansbro N, Dong C et al (2011) Blocking induction of T helper type 2 responses prevents development of disease in a model of childhood asthma. Clin Exp Immunol 165:19–28
  45. Corren J, Lemanske RF, Hanania NA et al (2011) Lebrikizumab treatment in adults with asthma. N Engl J Med 365:1088–1098
  46. Woodruff PG, Boushey HA, Dolganov GM et al (2007) Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids. Proc Natl Acad Sci U S A 104:15858–15863
  47. Maes T, Joos GF, Brusselle GG (2012) Targeting interleukin-4 in asthma: lost in translation? Am J Respir Cell Mol Biol (im Druck)
  48. Prenner BM, Bukofzer S, Behm S et al (2012) A randomized, double-blind, placebo-controlled study assessing the safety and tolerability of regadenoson in subjects with asthma or chronic obstructive pulmonary disease. J Nucl Cardiol (im Druck)
  49. Hinson KFW, Moon AJ, Plummer NS (1952) Broncho-pulmonary aspergillosis. A review and a report of eight new cases. Thorax 7:317–333
  50. Greenberger PA (2002) Allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol 110:685–692
  51. Knutsen AP, Bush RK, Demain JG et al (2012) Fungi and allergic lower respiratory tract diseases. J Allergy Clin Immunol 129:280–291 (Quiz: 292–293)
  52. Greenberger PA (1988) Allergic bronchopulmonary aspergillosis and fungoses. Clin Chest Med 9:599–608
  53. Crameri R, Hemmann S, Ismail C et al (1998) Disease-specific recombinant allergens for the diagnosis of allergic bronchopulmonary aspergillosis. Int Immunol 10:1211–1216
  54. Hartl D, Latzin P, Zissel G et al (2006) Chemokines indicate allergic bronchopulmonary aspergillosis in patients with cystic fibrosis. Am J Respir Crit Care Med 173:1370–1376
  55. Hartl D, Buckland KF, Hogaboam CM (2006) Chemokines in allergic aspergillosis—from animal models to human lung diseases. Inflamm Allergy Drug Targets 5:219–228
  56. Rosenberg M, Patterson R, Roberts M, Wang J (1978) The assessment of immunologic and clinical changes occurring during corticosteroid therapy for allergic bronchopulmonary aspergillosis. Am J Med 64:599–606
  57. Seaton A, Seaton RA, Wightman AJ (1994) Management of allergic bronchopulmonary aspergillosis without maintenance oral corticosteroids: a 15-year follow-up. QJM 87:529–537
  58. Stevens DA, Schwartz HJ, Lee JY et al (2000) A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis. N Engl J Med 342:756–762
  59. Wark PA, Hensley MJ, Saltos N et al (2003) Anti-inflammatory effect of itraconazole in stable allergic bronchopulmonary aspergillosis: a randomized controlled trial. J Allergy Clin Immunol 111:952–957
  60. Kanu A, Patel K (2008) Treatment of allergic bronchopulmonary aspergillosis (ABPA) in CF with anti-IgE antibody (omalizumab). Pediatr Pulmonol 43:1249–1251
  61. Ent CK van der, Hoekstra H, Rijkers GT (2007) Successful treatment of allergic bronchopulmonary aspergillosis with recombinant anti-IgE antibody. Thorax 62:276–277
  62. Reinhold-Keller E, Herlyn K, Wagner-Bastmeyer R, Gross WL (2005) Stable incidence of primary systemic vasculitides over five years: results from the German vasculitis register. Arthritis Rheum 53:93–99
  63. Harrold LR, Andrade SE, Go AS et al (2005) Incidence of Churg-Strauss syndrome in asthma drug users: a population-based perspective. J Rheumatol 32:1076–1080
  64. Vaglio A, Martorana D, Maggiore U et al (2007) HLA-DRB4 as a genetic risk factor for Churg-Strauss syndrome. Arthritis Rheum 56:3159–3166
  65. Guillevin L, Lhote F, Gayraud M et al (1996) Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine (Baltimore) 75:17–28
  66. Cohen P, Pagnoux C, Mahr A et al (2007) Churg-Strauss syndrome with poor-prognosis factors: a prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in 48 patients. Arthritis Rheum 57:686–693
  67. Zwerina J (2008) Churg-Strauss syndrome. Z Rheumatol 67:137–143 (Quiz: 144)
  68. Ribi C, Cohen P, Pagnoux C et al (2008) Treatment of Churg-Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients. Arthritis Rheum 58:586–594
  69. Koukoulaki M, Smith KG, Jayne DR (2006) Rituximab in Churg-Strauss syndrome. Ann Rheum Dis 65:557–559
  70. Cartin-Ceba R, Keogh KA, Specks U et al (2011) Rituximab for the treatment of Churg-Strauss syndrome with renal involvement. Nephrol Dial Transplant 26:2865–2871
  71. Rosenwasser LJ, Rothenberg ME (2010) IL-5 pathway inhibition in the treatment of asthma and Churg-Strauss syndrome. J Allergy Clin Immunol 125:1245–1246
  72. Sennekamp J, Joest M (2008) Recent advances in extrinsic allergic alveolitis. Pneumologie 62:51–54
  73. Sennekamp J, Müller-Wening D, Amthor M et al (2007) Guidelines for diagnosing extrinsic allergic alveolitis (hypersensitivity pneumonitis) (German Extrinsic Allergic Alveolitis Study Group). Pneumologie 61:52–56
  74. Hartman TE (2003) The HRCT features of extrinsic allergic alveolitis. Semin Respir Crit Care Med 24:419–426
  75. Lee TH, Wraith DG, Bennett CO, Bentley AP (1983) Budgerigar fancier’s lung. The persistence of budgerigar precipitins and the recovery of lung function after cessation of avian exposure. Clin Allergy 13:197–202
  76. Vogelmeier C, Mazur G, Pethran A et al (1995) Immunopathogenesis of extrinsic allergic alveolitis. Immun Infekt 23:86–91
• 作者单位：1. Klinik für Innere Medizin, Schwerpunkt Pneumologie, Philipps-Universit?t Marburg, Baldingerstr. 1, 35043 Marburg, Deutschland
• ISSN：1432-1289

文摘

Allergische Erkrankungen der Lunge k?nnen die Atemwege, das Lungenparenchym und die Gef??e der Lunge betreffen. Dazu geh?ren das exogen-allergische Asthma bronchiale, die exogen-allergische Alveolitis, die allergische bronchopulmonale Aspergillose und das Churg-Strauss-Syndrom. In Bezug auf die Art der allergischen Reaktion und deren pathophysiologische Konsequenzen unterscheiden sich die Krankheitsentit?ten stark. Das therapeutische Vorgehen h?ngt von der vorliegenden Erkrankung ab. In diesem Zusammenhang werden Biologika, die spezifisch und kausal in die Erkrankung eingreifen, zukünftig m?glicherweise eine gr??ere Rolle spielen.